Proactive Brokers Analysis - Thursday, August 14, 2014 by Proactive Investors Admedus starts shipping CardioCel® to the U.S. from WA facility
The commencement of CardioCel® shipments to the U.S. from Admedus’ Western Australia facility is a key milestone.Notably, it also indicates that the company is ready to meet global demand for the product as it secures approval in other jurisdictions.That 9 centres in the U.S. market are using the product which includes some of the leading cardiovascular surgical units in the country is encouraging.The facility will also enable Admedus to undertake additional product development to expand the range of regenerative tissue products. Upcoming share price catalysts that could re-rate the company include:
- Extending the use of CardioCel® for an expanded range of indications in cardiovascular surgery;
- Expanding regenerative tissue portfolio and explore the use of ADAPT® prepared tissue for additional surgical applications that have the potential to increase revenue in the future;
- Further data from the HSV-2 vaccine Phase 1 Study to be released this quarter;
- Initial Asian market approval for CardioCel®;
- Initiation of HSV-2 Phase II; and
- Initiation of HPV Phase I.
Summary- thats Proactive, Baillieu Holst, Pattersons, RBS Morgans, Motley Fool, Channel 9 Perth, Pr Fraser, Pr Tom Karl of Qsld, Dr Leo Neethling, Dr Tesla, and also "some of the leading [US] cardiovascular surgical units in the country and now even WA Premier Colin Barnett promoting the AHZ factory & stock ---what more bullish sign do you need?
AHZ Price at posting:
16.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)